Johnson & Johnson (JNJ) reported fourth-quarter earnings above Wall Street analyst estimates on Tuesday, but sales missed expectations and the diversified medical and personal care products maker guided 2013 earnings lower. The maker of a wide array of medical products from over-the-counter medications like Tylenol to surgical implants such as hip and knee replacements said Q4 EPS rose 5% to $1.19, beating expectations by 2 cents. Sales climbed 8%